Novel solid forms of tacedinaline
AssigneeThe Broad Institute, Inc.
InventorsEdward Holson, Florence F. Wagner, G. Patrick Stahly
Life of this patent
Estimating the term…
Abstract
Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Form B, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Form B, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
Claims14
A solid form of crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide Form B (tacedinaline Form B), crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide TFA salt, or amorphous 4-(acetylamino)-N-(2-aminophenyl)benzamide.
A method of preparing a solid form of 4-(acetylamino)-N-(2-aminophenyl)benzamide, comprising preparing any of crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide Form B, crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide TFA salt, or amorphous 4-(acetylamino)-N-(2-aminophenyl)benzamide, and converting it to a different solid form.
A method of treating a panic disorder or a post-traumatic stress disorder in a subject, said method comprising administering crystalline 4-(acetylamino)-N-(2-aminophenyl) benzamide Form B to said subject.
A method of treating a panic disorder or a post-traumatic stress disorder in a subject, said method comprising administering a pharmaceutical composition comprising crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide Form B to said subject.
A method of treating a panic disorder or a post-traumatic stress disorder in a subject, said method comprising administering 0.001 mg/kg to 50 mg/kg per day of crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide Form B to said subject, for at least two consecutive days.
A method of treating a panic disorder or a post-traumatic stress disorder in a subject, said method comprising administering up to 0.4 mg/kg per day of crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide Form B to said subject, for up to 14 consecutive days.
A method of treating a panic disorder or a post-traumatic stress disorder in a subject, said method comprising administering 0.001 mg/kg to 50 mg/kg of crystalline 4-(acetylamino)-N-(2-aminophenyl)benzamide Form B to said subject every other day, every third day, twice a week, or once a week.
Dependencies are inferred from the claim text.